COMPOSITION FOR USE IN THE TREATMENT OF ENDOMETRIOSIS AND SYMPTOMS ASSOCIATED WITH ENDOMETRIOSIS

Abstract

The present invention relates to a composition for oral use, in particular in form of food supplement comprising quercetin, extract of curcuma or curcumin, feverfew extract and a preparation comprising omega-3 and/or omega-6 and optionally nicotinamide and/or 5-methyltetrahydrofolate calcium salt. Moreover, the present invention relates to the use of such composition for the treatment of endometriosis symptoms and in reducing endometriosis outbreaks.

Claims

1. A composition comprising quercetin, an extract of a plant belonging to the genus Curcuma or Curcumin, an extract of a plant belonging to the species feverfew (Tanacetum parthenium) and a preparation comprising omega-3 and/or omega-6.

2. The composition according to claim 1 further comprising nicotinamide and/or 5-methyltetrahydrofolate calcium salt.

3. The composition according to claim 1 wherein said preparation comprising omega-3 and/or omega-6 is linseed oil.

4. The composition according to claim 1 wherein the amount of omega-3 is between 200 and 3000 mg.

5. The composition according to claim 2 wherein the amount of nicotinamide is between 5 and 100 mg and/or 5-methyltetrahydrofolate calcium salt is between 50 and 800 mg.

6. The composition according to claim 1 in a form selected from capsule, soft capsule, tablet, pill, jelly, powder, granule, emulsion, solution, or syrup.

7. The composition according to claim 1 wherein said composition is a food supplement, a nutraceutical, dietary and nutritional composition, a food product, a beverage, a neutraceutical, a medicament, a medicated food or a food for special medical purposes.

8. A method of treating endometriosis comprising administering the composition of claim 1 to a subject in need thereof.

9. The method of claim 8, wherein the subject exhibits one or more symptoms associated with endometriosis selected from acute and chronic pelvic pain, dyspareunia, dysmenorrhea, pain related to ovulation, pain related to urination, pain in the bowel functions, chronic physical fatigue, headache, female infertility and reducing endometriosis outbreaks.

10. A kit comprising quercetin, extract of curcuma or curcumin, feverfew extract and a preparation comprising omega-3 and/or omega-6 ad optionally nicotinamide and/or 5-methyltetrahydrofolate calcium salt.

11. The composition of claim 1, wherein the amount of omega-6 is between 50 and 2000 mg.

12. The composition of claim 1, wherein the amount of quercetin is between 50 and 1000 mg.

13. The composition of claim 1, wherein the amount of feverfew is between 3 and 40 mg.

14. The composition of claim 1, wherein the amount of curcuma is between 15 and 200 mg.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0011] The present invention describes a composition comprising, as main active ingredients, quercetin, extract of curcuma or curcumin, extract of feverfew and a preparation comprising omega-3 and/or omega-6 and optionally nicotinamide and/or 5-methyltetrahydrofolate calcium salt.

[0012] In the present description under the term preparation including omega-3 and/or omega-6 any preparation is meant, for example of natural, animal or plant origin, including essential fatty acids omega-3 and/or omega-6, preferably both of them. According to an embodiment the composition will include a concentration of omega-3 between 200 and 3000 mg and/or omega-6 between 50 and 2000 mg, in particular per dosage unit to be administered.

[0013] Examples of omega-3 and omega-6-based preparations are linseed oil, fish oil, Chia seeds, rape-seed oil. The linseed oil can be obtained by the person skilled in the art by means of conventional extraction techniques, for example it is obtained by squeezing previously dried or roasted flax seeds, preferably linseed oil in the composition will be in a concentration between 0.3 and 7 grams, in particular per dosage unit to be administered. According to an embodiment Linseed oil (Linum usitatissimum L., seeds, carrier: silicium dioxide) plv., Coating agent: Hydroxypropylmetylcellulose; Bulking agent: Dibasic calcium phosphate) will be used.

[0014] According to an embodiment the linseed oil used in the composition is titrated in linoleic acid and/or -linolenic acid, for example -linolenic acid between 400 mg and 2000 mg.

[0015] The composition of the invention further comprises an extract of plants belonging to the genus Curcuma, in particular belonging to the species Curcuma longa. For example the composition could include an extract of curcuma in a dose between 15 and 200 mg, preferably 20 mg, such extract will include curcuma active principle titrated for example in the above-mentioned range. Curcuma determines a reduction in the amount of estrogens, inhibition of metalloproteinases, it speeds up cellular apoptosis, it reduces TNF alfa immunity mediator, it reduces interleukin mediators, it inhibits angiogenesis by reducing VEGEF.

[0016] The composition of the invention further comprises an extract of plants belonging to the species Tanacetum parthenium (feverfew). According to an embodiment the composition could include an extract of feverfew titrated, for example in a dose between 3 and 100 mg, preferably 19.5 mg per dosage unit. Such extract will include parthenolide active principle titrated for example in the above-mentioned range. Feverfew inhibits prostaglandin PGE(2), and TNF alfa inhibits the proliferation of fibroblasts, it has an anti-hemicrania action and an action for reducing the inflammatory process. According to a preferred embodiment an extract of feverfew flower titrated in parthenolide between 0.3 and 0.6% will be used, such as for example the one available on the market by LCM IPA num. STP-QCPJHS404-001.

[0017] The herein described extracts could be obtained with the conventional techniques or purchase as available on the market.

[0018] The composition of the invention further comprises quercetin preferably in a dose between 50 mg and 1000 mg, in particular per dosage unit to be administered, preferably 200 mg. Quercetin reduces local estrogens by reducing FSH and LH (studies on animal model), it reduces VEGEF.

[0019] Quercetin and its obtaining modes/synthesis are widely described in the state of known art and therefore they do not require further examinations herein, by way for example it can be extracted from hawthorn, calendula, horse-chestnut tree, in particular Quercetin from flowers of Sophora japonica could be used.

[0020] The composition of the invention could further include nicotinamide and/or 5-methyltetrahydrofolate calcium salt. 5-methyltrahydrate calcium salt, reduces homocysteine (thromboembolic factor), whereas Nicotinamide (Vitamin B3) carries out an antiangiogenetic action. According to an embodiment the composition could include Nicotinamide, for example in a dose between 5 and 100 mg, preferably 20 mg, whereas 5-methyltetrahydrofolate calcium salt preferably in a dose between 100 mg and 600 mg.

[0021] The compositions according to the present invention can be formulated under any form and administration route and associated with any other component, in a variety of ways for example capsule, soft capsules, tablets, pills, jellies, powders or granules. Such excipients can be selected for example from those usually known in the state of art and include, but they are not limited thereto: a) carriers, such as for example sodium citrate and calcium phosphate, b) fillers such as for example starch, lactose, microcrystalline cellulose, sucrose, glucose, mannitol and colloidal silica, c) humectants, such as for example glycerol, d) disintegrant agents, such as alginate, calcium carbonate, starches, derivatives of starch, of cellulose and of polyvinylpyrrolidone, silicates and sodium carbonate e) ligands such as carboxymethylcellulose, alginates, jelly, polyvinylpyrrolidone, sucrose, polymer derivatives of cellulose, starch derivative f) retarding agents such as paraffin, cellulose polymers, esters of fatty acids g) absorption accelerators, such as quaternary ammonium compounds, h) wetting agents and surface-active agents such as cetyl alcohol and glycerol monostearate, i) adsorbents, such as benthic clays and kaolin, k) lubricants such as talcum, calcium stearate, magnesium stearate, polyethylene glycol, sodium lauryl sulphate, sodium stearyl fumarate j) glidants such as talcum, colloidal silica.

[0022] The forms of solid dosage, such as tablets, capsules, soft capsules, jellies, pills and granules, could be coated with enteric, gastric coatings or of other type known to the state of art. They could include opacifying agents and they can be of the type to allow the release of active ingredients only or preferably in a certain intestine tract, in case, in delayed way. Substances which can allow such delayed use include, but are not limited thereto, polymers and waxes.

[0023] The soft capsules could house antioxidant active substances in liquid form alone or in solutions, suspensions or emulsions of the active substances in a liquid solvent. The soft capsules could be characterized by a casing qualitatively similar to that of the stiff capsules, but thicker and softer. Liquid forms suitable to an oral for example are emulsions, solutions, prepared or extemporary suspensions, syrups and elisir. Excipients suitable to the formulations according to the present invention in liquid forms for oral use include, but they are not limited thereto, diluents such as water or other solvents, solubilising and emulsifying agents selected among ethyl alcohol, polyalcohols, propylene glycol, glycerol, polyethylenglycol and sorbitan esters. These formulations can even include sweeteners and aroma. The compositions will be for example a food supplement, a nutraceutical, dietary and nutritional composition a food product, a beverage, a neutraceutical, a medicament, a medicated food, a food for special medical purposes, a food. The compositions will be mainly intended to be used by human beings, but they could even be used on animals.

[0024] The compositions according to the present invention could include one or more suitable food ingredients and/or preservatives and/or acidifiers and/or antioxidant agents and/or immunostimulating agents and/or dyes and/or probiotic and/or prebiotic substances.

[0025] The combination of the above-mentioned active ingredients could be used formulated in one single composition according to the several above-described embodiments or in a kit including the different separated ingredients, for example in single compositions such as capsules, pills, tables for sequential or contemporary administration of the different ingredients.

[0026] The above-described compositions could be used/administered/taken for the treatment of endometriosis, in particular for the treatment of the symptoms associated to this pathology such as for example acute and chronic pelvic pain, dyspareunia, dysmenorrhea, pain related to ovulation, pain related to urination, pain in the bowel functions, chronic physical fatigue, headache, female infertility. Preferably, independently from the used formulation type, the combination of active ingredients according to the present invention will be administered with a daily dosage regime according to the above-mentioned concentrations.

EXPERIMENTAL SECTION

[0027] Clinical Study about Patients Affected by Endometriosis

[0028] A composition was prepared comprising linseed oil 1002 mg (alfa linolenic acid (omega 3) 432 mg and linoleic acid (omega 6) 172.8 mg), quercetin 200 mg, nicotinamide 20 mg, 5-Methyltetrahydrofolate calcium salt 400 mcg, curcuma titrated 20 mg, feverfew titrated 19.5 mg.

[0029] 90 patients were identified affected by endometriosis, divided into three groups each one constituted by 30 patients. The first group of 30 patients was treated with the above-mentioned composition including all active principles. Whereas the second group of 30 patients, with a composition including only linseed oil and 5-methyltetrahydrofolate calcium salt.

[0030] The third group of 30 patients affected by endometriosis took for the same duration of the first two groups a placebo and thus had the function of control group.

[0031] The first group constituted by 30 patients took 2 capsules per day, every twelve hours, for 3 months, of the composition including all active ingredients.

[0032] The second group di 30 patients took the equivalent dose of Linseed oil 1002 mg (alfa linolenic acid (omega 3) 432 mg and linoleic acid 172.8 mg (omega 6) still twice a day for oral administration (oa) associated to 5-methyltetrahydrofolate calcium salt (400 mcg) twice a day for oral administration. These two groups of patients affected by slight or severe endometriosis diagnosticated with the diagnostic protocol constituted by a bimanual vaginal and rectal positive examination, positive Ca125 serum dosage, positive NMR (pelvic Nuclear Magnetic Resonance) and histological diagnosis at the end of intake of products performed after diagnostic and operative laparoscopic surgery, were compared to the control group constituted by 30 women affected by endometriosis, positive to the protocol like the two groups treated with the above-mentioned compositions. The groups of affected patients (60) had the disease surgical diagnosis soon after the integrator intake.

[0033] Average age of affected groups I and II treated with the compositions: 34.0 years old

[0034] Average age of affected control group treated with con placebo: 35.2 years old.

[0035] Results

[0036] Symptomatology and comorbidity of the affected groups I and II group and affected placebo group each one constituted by 30 patients for a total of 90 subjects affected by endometriosis.

[0037] Cephalea: 15%

[0038] Cystitis: 12%

[0039] Muscular pain or fibromyalgia: 4%

[0040] Irritable colon: 15%

[0041] Past surgical operations: 42%

[0042] Positivity to Ca 125: 100% (exclusion criteria)

[0043] Dysmenorrhea VAS>=a 5: 62%

[0044] Dyspareunia VAS>=at 5: 37%

[0045] Chronic pelvic pain VAS>=at 5: 62%

[0046] Serum examinations performed in all three groups, group I, group II and control group:

[0047] 17BEstradiol on 21.sup.st gg of period before the intake in group I and II and in the last intake month

[0048] 17BEstradiol on 21.sup.st gg of period in the control group which was taking placebo, called Placebo group

[0049] Serum PGE2 group I, II, basal Placebo and in the last treatment month.

[0050] Group 1

[0051] The administration of the active principles constituted by Linseed oil 1002 mg (alfa linolenic acid (omega 3) 432 mg and linoleic acid 172.8 mg (omega 6)), Quercetin 200 mg, Nicotinamide 20 mg, 5-Methyltetrahydrofolate calcium salt 400 mcg, Curcuma titrated 20 mg, Feverfew titrated 19.5 mg, determined a reduction in symptomatology evaluated with VAS scale.

[0052] Pre-Treatment VAS Scale Symptomatology Values

[0053] (assimilated to placebo group)

[0054] Cephalea: 14%

[0055] Cystitis: 12%

[0056] Muscular pain or fibromyalgia: 4%

[0057] Irritable colon: 15%

[0058] Positivity to Ca 125: 100% with average value 61.4 U/ml (exclusion criterion if lower than 35 U/ml)

[0059] Dysmenorrhea VAS>=5: 62%

[0060] Dyspareunia VAS>=5: 30%

[0061] Chronic pelvic pain VAS>=at 5: 62%

[0062] Serum Examinations

[0063] 17 Beta Estradiol (on 21.sup.st day of period): average

[0064] value group 1: 184 pg/ml

[0065] Serum dosage of PGE2 average value group 1: 3404+/346 ng/l

[0066] 3* Month Treatment VAS Scale Symptomatology Values

[0067] Cephalea: 4%

[0068] Cystitis: 2%

[0069] Muscular pain (fibromyalgia): 1%

[0070] Irritable colon: 6%

[0071] Ca 125: 73%, Average Value 38 U/Ml

[0072] Dysmenorrhea VAS>=5:18%

[0073] Dyspareunia VAS>=5: 15%

[0074] Chronic pelvic pain VAS>=5: 18%

[0075] Serum Examinations

[0076] 17 Beta Estradiol (on 21.sup.st day of period): average

[0077] value group 1: 171 pg/ml

[0078] Serum dosage of PGE2 group 1:

[0079] 1377+/326 ng/l

[0080] Group 2

[0081] The administration of the active principles constituted by Linseed oil 1002 mg (alfa linolenic acid (omega 3) 432 mg and linoleic acid 172.8 mg (omega 6)), and 5-Methyltetrahydrofolate calcium salt 400 mcg, determined a reduction in the symptomatology evaluated with VAS scale and in the serum values of the marker of PGE2 inflammation, lower reduction than Group I taking all components, such differences are statistically significant and show the powerful and sole synergic action of the so-combined composition.

[0082] Pre-Treatment VAS Scale Values (Assimilable to Placebo Group)

[0083] Cephalea: 14%

[0084] Cystitis: 12%

[0085] Muscular pain or fibromyalgia: 4%

[0086] Irritable colon: 15%

[0087] Positivity to Ca 125: 100% average value 61.4 U/ml (exclusion criterion if lower than 35 U/ml)

[0088] Dysmenorrhea VAS>=5: 62%

[0089] Dyspareunia VAS>=5: 30%

[0090] Chronic pelvic pain VAS>=at 5: 62%

[0091] Serum Examinations

[0092] Dosage 17 Beta Estradiol on 21.sup.st day of period

[0093] average value group 2: 176 pg/ml

[0094] Serum dosage PGE2 average value group 2: [0095] 3305+/396 ng/ml

[0096] 3* Month Treatment VAS Scale Symptomatology Values

[0097] with the composition of only two components, Linseed oil 1002 mg (linolenic acid, 432 mg, linoleic acid, 172.8) and 5-Methyltetrahydrofolate calcium salt 400 mcg,

[0098] Cephalea: 12%

[0099] Cystitis: 8%

[0100] Muscular pain (fibromyalgia): 4%

[0101] Irritable colon: 12%

[0102] Ca 125: 97% average value 52.6 U/ml

[0103] Dysmenorrhea VAS>=5: 41%

[0104] Dyspareunia VAS>=5: 37%

[0105] Chronic pelvic pain VAS>=5: 45%

[0106] Serum Examinations

[0107] Dosage 17 Beta Estradiol (on 21.sup.st day of period)

[0108] group 2: 168 pg/ml

[0109] Serum dosage PGE2 group 2: [0110] 2605+/396 ng/ml

[0111] Placebo group like group I and II pre-treatment [0112] Cephalea: 14% [0113] Cystitis: 12% [0114] Muscular pain or fibromyalgia: 4% [0115] Irritable colon: 15% [0116] Positivity to Ca 125: 100% average value 61.4 U/ml (exclusion criterion if lower than 35 U/ml)) [0117] Dysmenorrhea VAS>=5: 62% [0118] Dyspareunia VAS>=5: 30% [0119] Chronic pelvic pain VAS>=a 5: 62%

[0120] Serum Examinations

[0121] Dosage 17 Beta Estradiol (on 21.sup.st day of period) placebo group: 164 pg/ml

[0122] Serum dosage PGE2 average value placebo group: [0123] 3481+/462 ng/l

[0124] Placebo Group after 3-Month Treatment (Placebo)

[0125] Cephalea: 13%

[0126] Cystitis: 12%

[0127] Muscular pain or fibromyalgia: 4%

[0128] Irritable colon: 15%

[0129] Positivity to Ca 125: 100% (exclusion criterion if lower than 35 U/ml)

[0130] Dysmenorrhea VAS>=5: 60%

[0131] Dyspareunia VAS>=5: 30%

[0132] Chronic pelvic pain VAS>=a 5: 60%

[0133] Serum Examinations

[0134] Dosage 17 Beta Estradiol (on 21.sup.st day of period) placebo group: 154 pg/ml

[0135] Serum dosage of PGE2 placebo group: [0136] 3469+/451 ng/l